The Sunshine Reporter

Delveinsight Business Research LLP

The End-Stage Renal Disease (ESRD) Pipeline report embraces in-depth commercial and clinical assessment of the End-Stage Renal Disease (ESRD) pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease (ESRD) collaborations, mergers, acquisition, funding, designations, and other product-related details.

End-Stage Renal Disease (ESRD) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights about companies that are developing therapies for the treatment of End-Stage Renal Disease (ESRD) with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the End-Stage Renal Disease (ESRD) Treatment.

• End-Stage Renal Disease (ESRD) key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• End-Stage Renal Disease (ESRD) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the End-Stage Renal Disease (ESRD) market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

End-Stage Renal Disease (ESRD) Therapeutics Landscape

Diabetic nephropathy (DN) is one of the most common complications of diabetes and the leading cause of end-stage renal disease (ESRD). Approximately 30–40% of diabetes mellitus patients in the world progress to ESRD, which emphasizes the effect of genetic factors on DN. 

End-Stage Renal Disease (ESRD) therapeutics market size is expected to increase during the forecast period owing to the growing prevalence of the disease and the expected launch of the emerging therapies.

End-Stage Renal Disease (ESRD) companies:

• Aronora

• Merck

• Rockwell Medical Technologies

• Dynavax Technologies Corporation

And many others.

End-Stage Renal Disease (ESRD) therapies covered in the report include:

• Intravenous Triferic

• AB002

• MK-2060

And many more.

Request for Sample Pages @ End-Stage Renal Disease (ESRD) Emerging Therapies and Key Companies

Table of Content

1. Report Introduction

2. End-Stage Renal Disease (ESRD) 

3. End-Stage Renal Disease (ESRD) Current Treatment Patterns

4. End-Stage Renal Disease (ESRD) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. End-Stage Renal Disease (ESRD) Late Stage Products (Phase-III)

7. End-Stage Renal Disease (ESRD) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. End-Stage Renal Disease (ESRD) Discontinued Products

13. End-Stage Renal Disease (ESRD) Product Profiles

14. End-Stage Renal Disease (ESRD) Key Companies

15. End-Stage Renal Disease (ESRD) Key Products

16. Dormant and Discontinued Products

17. End-Stage Renal Disease (ESRD) Unmet Needs

18. End-Stage Renal Disease (ESRD) Future Perspectives

19. End-Stage Renal Disease (ESRD) Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report: https://www.delveinsight.com/sample-request/end-stage-renal-disease-pipeline-insight

Latest Healthcare Report by DelveInsight

Global Kinase Inhibitor in Autoimmune Diseases Market

DelveInsight’s “Global Kinase Inhibitor in Autoimmune Diseases  Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/